Efficacy of Escitalopram Oxalate for Patients with Post-stroke Depression

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Apr 6

PMID 29620632

Citations 1

Authors

Ji-Hua Xu

Peng Jiang

Affiliations

Soon will be listed here.

Abstract

This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD).A total of 115 patients with PSD were included in this study. A total of 65 patients underwent ESO (Intervention group). A total of 50 patients received acupressure (Control group). The outcome measurements included Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS). In addition, we also recorded the adverse events in this study.At the end of 8-week treatment, ESO showed greater efficacy in depression, measured by MADRS (P < .01); anxiety, measured by HAM-A scale (P < .01); and disability, measured by SDS (P < .01), compared to acupressure. Additionally, there were not significant differences regarding adverse events between two groups (P > .05).The present results indicate that ESO can decrease symptoms of patients with PSD.

Citing Articles

Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Chollet F, Rigal J, Marque P, Barbieux-Guillot M, Raposo N, Fabry V Curr Neurol Neurosci Rep. 2018; 18(12):100.

PMID: 30353288 DOI: 10.1007/s11910-018-0904-9.

References

Thomas S, Coates E, das Nair R, Lincoln N, Cooper C, Palmer R . Behavioural Activation Therapy for Depression after Stroke (BEADS): a study protocol for a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. Pilot Feasibility Stud. 2016; 2:45. PMC: 5153669. DOI: 10.1186/s40814-016-0072-0. View

Burke W, Gergel I, Bose A . Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002; 63(4):331-6. DOI: 10.4088/jcp.v63n0410. View

Maity N, Ghosal M, Gupta A, Sil A, Chakraborty S, Chatterjee S . Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014; 46(4):433-7. PMC: 4118540. DOI: 10.4103/0253-7613.135959. View

Wang Z, Zhu M, Su Z, Guan B, Wang A, Wang Y . Post-stroke depression: different characteristics based on follow-up stage and gender-a cohort perspective study from Mainland China. Neurol Res. 2017; 39(11):996-1005. DOI: 10.1080/01616412.2017.1364514. View

Knapp P, Campbell Burton C, Holmes J, Murray J, Gillespie D, Lightbody C . Interventions for treating anxiety after stroke. Cochrane Database Syst Rev. 2017; 5:CD008860. PMC: 6481423. DOI: 10.1002/14651858.CD008860.pub3. View

Waugh J, Goa K . Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003; 17(5):343-62. DOI: 10.2165/00023210-200317050-00004. View

Esparrago Llorca G, Castilla-Guerra L, Fernandez Moreno M, Ruiz Doblado S, Jimenez Hernandez M . Post-stroke depression: an update. Neurologia. 2012; 30(1):23-31. DOI: 10.1016/j.nrl.2012.06.008. View

Gaete J, Bogousslavsky J . Post-stroke depression. Expert Rev Neurother. 2007; 8(1):75-92. DOI: 10.1586/14737175.8.1.75. View

Xu X, Zou D, Shen L, Liu Y, Zhou X, Pu J . Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016; 95(45):e5349. PMC: 5106064. DOI: 10.1097/MD.0000000000005349. View

10.

Zhang L, Zhao M, Sui R . Cerebellar Fastigial Nucleus Electrical Stimulation Alleviates Depressive-Like Behaviors in Post-Stroke Depression Rat Model and Potential Mechanisms. Cell Physiol Biochem. 2017; 41(4):1403-1412. DOI: 10.1159/000467940. View

11.

Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-58. DOI: 10.1016/S0140-6736(09)60046-5. View

12.

Hoschl C, Svestka J . Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother. 2008; 8(4):537-52. DOI: 10.1586/14737175.8.4.537. View

13.

Ibeneme S, Nwosu A, Ibeneme G, Bakare M, Fortwengel G, Limaye D . Distribution of symptoms of post-stroke depression in relation to some characteristics of the vulnerable patients in socio-cultural context. Afr Health Sci. 2017; 17(1):70-78. PMC: 5636229. DOI: 10.4314/ahs.v17i1.10. View

14.

Chen Y, Guo J, Zhan S, Patel N . Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006; 40(12):2115-22. DOI: 10.1345/aph.1H389. View

15.

Nickel A, Thomalla G . Post-Stroke Depression: Impact of Lesion Location and Methodological Limitations-A Topical Review. Front Neurol. 2017; 8:498. PMC: 5613107. DOI: 10.3389/fneur.2017.00498. View

16.

Mohamed S, Osatuke K, Aslam M, Kasckow J . Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother. 2006; 4(3):201-9. DOI: 10.1016/j.amjopharm.2006.08.001. View

17.

Mead G, Hsieh C, Lee R, Kutlubaev M, Claxton A, Hankey G . Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012; 11:CD009286. PMC: 6465036. DOI: 10.1002/14651858.CD009286.pub2. View

18.

Niakosari Hadidi N, Huna Wagner R, Lindquist R . Nonpharmacological Treatments for Post-Stroke Depression: An Integrative Review of the Literature. Res Gerontol Nurs. 2017; 10(4):182-195. DOI: 10.3928/19404921-20170524-02. View

19.

Hackett M, Kohler S, OBrien J, Mead G . Neuropsychiatric outcomes of stroke. Lancet Neurol. 2014; 13(5):525-34. DOI: 10.1016/S1474-4422(14)70016-X. View

20.

Feng C, Fang M, Liu X . The neurobiological pathogenesis of poststroke depression. ScientificWorldJournal. 2014; 2014:521349. PMC: 3973123. DOI: 10.1155/2014/521349. View